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Abstract: West Nile Virus (WNV) is a mosquito-transmitted flavivirus which causes encephalitis
especially in elderly and immunocompromised individuals. Previous studies have suggested
the protective role of the Toll-like receptor 3 (TLR3) pathway against WNV entry into the brain,
while the WNV non-structural protein 1 (NS1) interferes with the TLR3 signaling pathway, besides being
a component of viral genome replication machinery. In this study, we investigated whether immunization
with NS1 could protect against WNV neuroinvasion in the context of TLR3 deficiency. We immunized
mice with either an intact or deleted TLR3 system (TLR3KO) with WNV envelope glycoprotein (gE)
protein, NS1, or a combination of gE and NS1. Immunization with gE or gE/NS1, but not with
NS1 alone, induced WNV neutralizing antibodies and protected against WNV brain invasion
and inflammation. The presence of intact TLR3 signaling had no apparent effect on WNV brain
invasion. However, mock-immunized TLR3KO mice had higher inflammatory cell invasion upon
WNV brain infection than NS1-immunized TLR3KO mice and wild type mice. Thus, immunization
against NS1 may reduce brain inflammation in a context of TLR3 signaling deficiency.
Keywords: NS1; TLR3; West Nile Virus; immunity; pathogenesis; subunit vaccine; West Nile
neuroinvasive disease
1. Introduction
West Nile Virus (WNV) is a neurotropic flavivirus that naturally cycles between wild birds
and Culex spp. mosquitoes which may incidentally transmit the virus to humans and other mammals [1].
Importantly, the virus can cause a fatal neurological disease in humans and horses, although only
a minor percentage of infected individuals will show any disease symptoms. In addition, the virus
may cause disease and mortality in several bird species [2–4]. Vaccines to protect horses and domestic
birds have been in use for a long time. In contrast, a vaccine for humans has not yet been licensed,
although a variety of vaccine candidates have been proposed, including vaccines based on inactivated
viruses, recombinant viruses, chimeric viruses, recombinant DNA, purified proteins, or combinations
thereof [5–14]. Such candidate vaccines have been extensively tested, mostly in mouse models but also
in Syrian hamsters [13,15–25] and nonhuman primates [26].
WNV envelope glycoprotein (gE) is a key component of anti-WNV vaccines since immunization
with gE confers protective humoral immunity against WNV [13,14,18,24,27–29]. WNV gE is the major
receptor-binding protein and comprises the epitopes for neutralizing antibodies that map to a region
termed domain III (aa 299–400; indicated in yellow in Figure 1) [30]. Besides gE, additional viral
antigens have been included in anti-WNV vaccines, such as the membrane (prM) and the capsid (C)
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proteins to generate virus-like particles, and nonstructural proteins, such as the NS1 glycoprotein (NS1)
(indicated in gray in Figure 1).
Including NS1 into vaccines could be a promising approach in particular to provide additional
protection for individuals with weaning immune responses against gE or with defects in the Toll-like
receptor 3 (TLR3) system. NS1 is a multifunctional protein that is both associated with cell membranes
and secreted in the bloodstream as a hexamer. Besides being an essential component of the viral
replication complex [31], WNV NS1 is involved in neuroinvasion and evasion of the host immune
response [32]. WNV NS1 has been demonstrated to antagonize TLR3 signaling and thus the establishment
of a TLR3-dependent antiviral state in neurons [33], although this finding was not observed in another
study [34]. WNV NS1 has also been reported to antagonize complement activation [23] and to selectively
bind brain endothelial cells resulting in endothelial hyper-permeability and disruption of the blood–brain
barrier [35]. Immunization of mice against NS1 has been shown to provide protection against lethal
infection with neurovirulent WNV strains [36], but NS1 has also shown poor immunogenicity in some
animal models [37]. Data on the role of the TLR3 pathway in WNV protection or pathogenesis are
also conflicting. While some studies suggested a protective role of the TLR3 system against WNV [38]
and its antagonizing by NS1, important for WNV virulence [33], others have demonstrated that the TLR3
system is required for allowing WNV entry into the brain, thus representing a preconditional system
for the development of lethal encephalitis [39]. Similarly, others have linked the increased frequency of
WNV encephalitis in elderly humans to increased TLR3 signaling, which may lead to elevated cytokine
levels to contribute to the permeability of the blood–brain barrier [40].
Many studies on WNV pathogenesis and immunity focus on highly virulent American strains,
such as the cluster of WNV NY99 isolates [16,39,41,42]. In this study we used the ITA09 strain,
which was isolated from an asymptomatic blood donor in Italy but was still neurovirulent in the mouse
model [43,44]. This strain is representative of WNV lineage 1, which circulates in Western Europe
and the Mediterranean area [45].
With these considerations and partly conflicting findings in mind, we set out to address the role of
immunization against WNV NS1 in mice with either an intact or else genetically deleted TLR3 system.
For this purpose, we produced recombinant gE and NS1 proteins and immunized wild type (WT) mice
and congenic TLR3-knockout mice (TLR3KO) with either gE alone or NS1 alone or gE in combination
with NS1, followed by challenge infection with WNV ITA09. Based on survival, clinical WNV
symptoms, measurements of WNV viremia, serostatus against gE and/or NS1, WNV detection in
the brain, measurement of inflammatory cytokines, and immune cell invasion into the brain in response
to WNV, we found that neither the TLR3 pathway nor antibodies against NS1 had a principal effect on
WNV brain invasion. However, the degree of cellular infiltration in the brain was less severe in WT
mice than in TLR3KO mice. Yet, in comparison to non-immunized siblings, TLR3KO mice immunized
against WNV NS1 showed reduced cell infiltration to the WNV-infected brain, which was comparable
to the degree observed in WT mice with or without previous vaccination against NS1.
2. Materials and Methods
2.1. Ethics Statement
Ethical justification of the study as well as animal care, use, and termination criteria were
approved by the Cantonal Veterinary Office (Zurich, Switzerland) under license number ZH57/2014
(Approval date: 5 February 2014). Housing and experimental procedures were in strict accordance
with Swiss animal protection law and in conformity with the European Convention for the Protection
of Vertebrate Animals used for Experimental Purposes.
2.2. Construction of Recombinant Baculoviruses for Expression of WNV Glycoprotein E- and NS1-Fragments
The nucleotide sequences encoding the external fragments (ectodomains without stop codons)
of WNV glycoproteins E and NS1 (Figure 1), respectively, were codon-optimized for expression in
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insect cells. Moreover, two variants of each construct were made, one with a C-terminal c-myc tag
without a stop codon, the other with two C-terminal tags (V5 and 6xhis followed by a stop codon)
before they were commercially synthesized and cloned into the BamHI restriction enzyme site of
the pUC57 vector (GenScript, Piscataway, NJ, USA). The synthetic constructs were excised by BamHI
digestion to be cloned into the BamHI site of a pDONR221-derived Gateway vector, which comprised
an upstream synthetic baculovirus signal sequence as well as a downstream GST tag prior to the stop
codon and which provided attL1 and attL2 sequences for targeted recombination into the pDEST8
vector by means of the Gateway LR reaction (Life Technologies, Carlsbad, CA, USA). The resulting
pDEST8 constructs were sequenced to verify the integrity and orientation of the inserts before being
transposed into baculovirus bacmids (Life Technologies’ Bac-to-Bac Baculovirus Expression System).
The inserts of the bacmids were again verified by sequencing before the bacmids were used to transfect
Sf9 cells in order to reconstitute the desired recombinant baculoviruses.
2.3. Virus Strains and Cell Lines
All work with infectious WNV was done under biosafety level 3 (BSL-3) conditions. WNV Italy 09
(ITA09) is a WNV lineage 1 strain which was isolated in Vero cells from a viremic blood donor,
as reported [44]. The WNV ITA09 stock used for experiments was at passage 2. WNV Egypt-101
(Eg-101, kindly provided by the OIE Reference Centre for West Nile Disease, Istituto Zooprofilattico
Sperimentale “G. Caporale”, Teramo, Italy) is a non-lethal WNV lineage 1 strain which was
used for neutralization assays. Vero cells (ATCC CCL81™; American Type Culture Collection,
Manassas, VA, USA), an African Green Monkey kidney-derived cell line, were used for WNV
expansion, titration, and neutralization assays. Vero cells were grown in Dulbecco modified Eagle
medium (DMEM), supplemented with 10% fetal bovine serum (FBS). Spodoptera frugiperda-derived Sf9
and Mimic Sf9 were obtained from Thermo Fisher Scientific (Reinach, BL, Switzerland) and maintained
as monolayers at 27 ◦C. Conventional Sf9 cells were cultured in Grace’s insect medium supplemented
with 10% FCS and used for transfections, viral stock production, and ELISA antigen production.
The Mimic SF9 cells were cultured in serum-free SF900 III medium (Thermo Fisher Scientific) and used
for expression of immunizing antigens.
2.4. Animals and Protection Study
C57BL/6J, BALB/c, and B6;129S1-Tlr3tm1Flv/J (TLR3 knockout; TLR3KO) female mice were used
for animal experiments. Female WT C57BL/6 mice (6–8 weeks old), and BALB/c mice (6–8 weeks old)
were purchased from Charles River (Germany) and housed at the Institute of Laboratory Animal
Sciences. TLR3KO mice (6–8 weeks old) were bred in-house. Table 1 below provides the names
designated for the groups used in the protection study.
In the protection study (Table 1), 6–8 weeks old female WT C57BL/6 and TLR3KO mice (n = 5) were
immunized subcutaneously (s.c.) thrice with either 5 µg of gE, NS1, or gE+NS1 supplemented
with 10 µg of Quil-A adjuvant or 1/10th of a horse dose of Equip WNV commercial vaccine
(Zoetis, Delémont, Switzerland), used as a positive control for the immunization. Negative control mice
were vaccinated with protein elution buffer supplemented with 10 µg Quil-A adjuvant. Sera samples
after the final booster immunization were tested for neutralizing antibodies and gE or NS1 specific
antibodies. All the groups were then inoculated with 105 plaque forming units (pfu) of WNV
lineage 1 ITA09 strain intraperitoneally (i.p.). Mice were scored twice daily for signs of infection
and euthanized 20 days after infection or earlier depending on whether they reached the end point score.
Blood samples were collected at days 2 and 4 post inoculation to measure the viral burden in the plasma.
Brain and spleen samples from all the mice were collected after euthanasia for various analyses.
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Table 1. Overview of group designations, mouse genotypes, and vaccinating antigens.
Group # Genotype Vaccination
A 3 aWT C57BL/6 Commercial
B 5 WT C57BL/6 cgE
C 5 WT C57BL/6 dNS1
D 5 WT C57BL/6 gE + NS1
E 5 WT C57BL/6 Mock (ePBS + adjuvant)
F 3 bTLR3KO Commercial
G 5 TLR3KO gE
H 5 TLR3KO NS1
J 5 TLR3KO gE + NS1
K 5 TLR3KO Mock (PBS + adjuvant)
aWT: wild type; bTLR3KO: Toll-like receptor 3 knockout; cgE: envelope glycoprotein; dNS1: non-structural protein 1;
ePBS: phosphate-buffered saline.
2.5. Clinical Scoring
As described previously [13], the clinical signs of WNV infection in mice were subdivided into
three categories: loss of body weight, pain-associated behavior, and disease-related physical changes.
Table 2 summarizes our scoring system.
Table 2. Clinical scoring.
Symptom Observation Score
Loss of body weight Body weight within range of untreated group 0
1–5% loss of body weight 1
>5–15% loss 2
>15% loss 3
Pain-associated behavior Normal activity 0
Reduced activity, moving after slight impulse, shivering 1
Inactive, apathic, moving after moderate impulse 2
Ataxia, paralysis, not moving even after moderate
stimulation 3
Normal posture 0
Hunched posture 1
Hunched posture, head lying on the cage floor 2
Lying prone on the cage floor 3
Physical changes Normal hair coat 0
Ruﬄed 1
Ruﬄed, loss of fur, ungroomed 2
Normal eyes 0
Eyes closed or squinted, no discharge 1
Eyes closed or squinted, with discharge 2
Prior to the WNV challenge, all the animals were checked for two weeks and had a score of 0 in
all three categories. After WNV inoculation, the animals were scored twice each day for all the traits.
Termination criteria: an animal was terminated by euthanasia if it reached a combined score of 6
or more from all categories or if it reached a score of 3 either in the category loss-of-body-weight or in
the category pain-associated-behavior.
2.6. ELISA for gE and NS1 Specific Antibodies
First, glutathione-conjugated casein (kindly provided by Dr. Kurt Tobler, University of Zurich,
Switzerland) at 1:500 in coating buffer (10 mM Na2CO3, 40 mM NaHCO3, pH9.6) was incubated over
night at 4 ◦C in flat-bottom ELISA plates (Fisher Scientific AG, Wohlen, Switzerland). Then, excess
antigen-binding sites were blocked with blocking solution (2% milk powder in phosphate-buffered saline
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(PBS), supplemented with Tween 20, pH 7.4 (PBST). In the next step, GST-fusion proteins (separate plates
for gE and NS1, respectively) were allowed to bind as ELISA antigens to the glutathione molecules in
a native manner. For this purpose, the fusion proteins were diluted in blocking solution in a manner to
provide an optical density at 450 nm (OD450) of 1.0, upon analysis with the c-myc monoclonal antibody
(Life technologies, Carlsbad, CA, USA). Now, mouse sera, prediluted in blocking buffer, were incubated
with the antigens. Irrespective of the vaccinating antigen(s), each serum was tested against both NS1-
and gE-antigens in order to control for unspecific reactions. Moreover, each serum was tested in
two separate dilutions, namely at 1:1000 and at 1:100. Then, goat anti-mouse-horseradish peroxisase
(HRP)-conjugated secondary antibody (GE Healthcare, Opfikon, Switzerland) diluted in blocking
buffer at 1:1000 was added. Finally, 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Thermo Scientific,
Basel, Switzerland) was prepared according to the manufacturer’s protocol and 100 µL were added per
well. The reactions were left at room temperature and stopped after 30 min using an equal volume
of 2 M H2SO4, 10 min before the absorbance was measured at 450 nm. All volumes were 50 µL and all
incubations were at 37 ◦C for one hour, except where stated otherwise. Three washings with 300 µL
PBST were done between each step. The final wash before addition of the substrate solution was done
with plain PBS after five times washing with PBST.
2.7. WNV Neutralization Test
Neutralizing antibodies in mouse sera were titrated by plaque reduction neutralization assay
(PRNT) [46]. In brief, two-fold serial dilutions of each serum (from 1:80 to 1:2560) were mixed with
an equal volume of medium containing approximately 50–60 pfu of WNV lineage 1 (Eg101 strain)
and incubated for 75 min at 37 ◦C before inoculation onto sub-confluent monolayers of Vero cells
(about 5 × 105 cells/well in 6-well plates). After adsorption for 1 h at 37 ◦C, the inoculum was
removed and the cells were overlaid with a gel made of 50% 2×minimal essential medium (2×MEM)
medium (with 4% FBS) and 50% agar noble 2% w/v in sterilized water and incubated at 37 ◦C, 5% CO2.
After 3 days, a secondary overlay prepared as above, but with the addition of Neutral Red stain,
was added to the well, and on the fourth day plaques were detected as non-stained spots on the red
background. The neutralizing antibody titer was calculated as the reciprocal of the serum dilution
at which a 50% reduction of plaques (PRNT50) was observed compared to an inoculated control well
incubated in the absence of the test serum.
2.8. WNV RNA Detection in Plasma and Tissue Samples
For WNV RNA detection in plasma, brain, and spleen samples, total nucleic acids were extracted
from samples by using the MagNA Pure 96 SV nucleic acid purification kit (Roche, Basel, Switzerland).
For WNV RNA quantification, the NS5 sequence was targeted by real-time RT-PCR using a One Step
Real Time kit (Thermo Fisher Scientific, Waltham, MA, USA) as previously described [47]. Real time
reactions were run on a 7900 HT Sequence Detection System instrument (Thermo Fisher Scientific).
2.9. Cytokine Quantification
Brain tissue samples were immersed in 1 mL of RLT buffer and stored at –80 ◦C until further
processing. The samples were homogenized using an 18G needle and then centrifuged at 12,000× g
for 10 min. Total RNA was extracted from 200 µL of the total sample using a qiashredder
(Qiagen AG, Basel, Switzerland) and an RNeasy mini kit (Qiagen AG, Basel, Switzerland) according to
the manufacturer’s protocol. 500 ng of total RNA was reverse transcribed using a QuantiTect Reverse
Transcription kit (Qiagen AG, Basel, Switzerland) as per the protocol. Following reverse transcription,
cytokine expression in the brain was determined by conducting quantitative SYBR green-based real
time RT-PCR (real time qRT-PCR). The reaction mixture contained 2 µL of template cDNA (dilute 1
in 10), 10 µL of 2× SYBR green mix, and 500 nM of primers at a final volume of 20 µL. The initial
activation step for the HotStarTaq DNA polymerase was performed at 95 ◦C for 15 min followed
by 45 cycles of 95 ◦C for 15 s, 60 ◦C for 30 s, and 72 ◦C for 30 s, and an extension cycle at 72 ◦C
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for 5 min. The real time RT-PCR was carried out using the QuantStudio 7 Flex system. A control sample
containing no template was run with each assay and all the reactions were performed in duplicate to
ensure reproducibility. The authenticity of the amplified product was determined by melting curve
analysis. Relative expression of each target gene was calculated with the ∆∆Ct method using β-actin
as a house-keeping gene. The following primers were used: β-actin (fwd: 5′-TGG AAT CCC TGT GGG
ACC ATG AAA C-3′; rev: 5′-TAA AAC GCA GCT CAG TAA CAG TCC G-3′), TNFα (fwd: 5′-CGT
CGT AGC AAA CCA CCA AG-3′; rev: 5′-TTG AAG AGA ACC TGG GAG TAG ACA-3′) and IFNγ
(fwd: 5′-GCT CTG AGA CAA TGA ACG CT-3′; rev: 5′-AAA GAG ATA ATC TGG CTC TGC-3′).
2.10. Isolation of Leukocytes from Brain Tissues
Half of the brain was shortly rinsed in PBS and minced finely with a scalpel and a quarter of
it was transferred into a tube containing 1.5 mL of digestion buffer (RPMI with 10% FCS, 2 mM
HEPES, 0.4 mg/mL Collagenase type IV, and 2 mg/mL DNaseI). The sample was incubated at 37 ◦C.
After 45 min, the reaction was stopped with 0.5 M EDTA. The sample was then homogenized with
an 18G × 40 mm needle and filtered using a 70 µm cell strainer and centrifuged in a 1.5 mL Eppendorf
tube at 450× g for 8 min at 4 ◦C. The cell pellet was washed with 1 mL of cold PBS and centrifuged
at 450× g for 8 min at 4 ◦C. Supernatant was discarded. The cell pellet was resuspended in 1 mL 30%
Percoll and centrifuged at 12,000× g for 30 min at 4 ◦C. The upper layer containing myelin was removed
and 500 µL of cold PBS was added to the tube. The Percoll suspension was filtered using a 70 µm
cell strainer and centrifuged at 450× g for 8 min at 4 ◦C. The cell pellet was washed once with PBS
and then twice in 1 mL FACS buffer (PBS supplemented with 1% FCS, 5 mM EDTA, and 0.02% NaN3)
and centrifuged at 450× g for 8 min at 4 ◦C.
2.11. Analysis of Leukocyte Infiltration into the CNS by Flow Cytometry
The following antibodies were used: LIVE/DEAD Fixable Near-IR dead cell stain
(Life Technologies), CD45:PB (Biolegend, clone 104), CD11B:PE-Cy7 (Biolegend, clone M1/70),
Ly6G:FITC (Biolegend, clone 1A8), Ly6C:BV510 (Biolegend, clone HK1.4), and CD45.2:Alexa700
(Biolegend, clone 104). Cells were resuspended in 100 µL of antibody mix and incubated for 30 min
at 4 ◦C in the dark and then washed with FACS buffer and spun down at 450× g for 8 min at 4 ◦C.
Cells were fixed in 5% paraformaldehyde for 15 min and then washed twice with FACS buffer
and centrifuged at 450× g for 8 min at 4 ◦C. The cells were finally resuspended in 100 µL of FACS buffer.
All the data were collected using a Gallios flow cytometer (Beckman Coulter) and analyzed using FlowJo
software version 10 (FlowJo LLC). The gating of the flow cytometric data was performed according to
the guidelines for the use of flow cytometry and cell sorting in immunological studies [48], including
pre-gating on viable and single cells for analysis. Absolute cell numbers of each cell population were
calculated based on a defined number of counting beads (BD Bioscience, Calibrite beads) which were
added to the samples before the flow cytometric acquisition.
2.12. Histology of Brain Samples
Histological analysis of brain samples was performed after hematoxylin and eosin staining.
The severity of brain lesions was scored as follows: negative (0), mild lesions possibly associated with
viral infection (1), moderate lesions (2), and severe lesions (3).
2.13. Statistical Analysis
Serological and leukocyte infiltration data were analyzed using One Way ANOVA with Tukey’s
test and the Mann-Whitney test, respectively. All the statistical analyses were performed using
GraphPad Prism 6 software.
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3. Results
3.1. Construction of the Recombinant WNV gE and NS1 Proteins
DNAs encoding the relevant fragments of WNV gE and NS1, respectively, were commercially
synthesized (Figure 1) and introduced into the polyhedrine locus of recombinant baculovirus genome
bacmids by using Invitrogen’s Baculovirus Gateway technology, as described in Materials and Methods.
Proteins expressed from the resulting baculoviruses were to be used as immunizing antigens. The results
are shown in Supplementary Data 1 (Figure S1).
Moreover, shorter fragments of the gE and NS1 proteins were synthesized to serve as templates
for ELISA antigens. In the case of gE, domain III was fused to an N-terminal signal sequence
and C-terminally complemented with a c-myc tag and a GST fragment. In the case of NS1, a part
of the C-terminus was deleted before fusion to c-myc and GST. Recombinant baculovirus bacmids
were generated as above (Figure S2). The sequences and orientations of all four bacmid inserts were
confirmed by sequencing.
3.2. Susceptibility of C57BL/6J Mice to WNV ITA09 Infection and Immunogenicity of WNV Antigens
Since TLR3KO mice are bred on a 129/C57BL/6 background, we characterized the dose-dependent
outcome of WNV infection in C57BL/6 mice. As the inoculation of C57BL/6 mice with 105 pfu
of our WNV ITA09 stocks led to a consistent high-dose infection of the brain, followed by 100%
lethality (approximately 100 LD50 (lethal dose for 50% of the animals in the group), we decided to
use this dose for the upcoming vaccination-challenge experiments (Supplementary Data 2, Figure S3).
Moreover, the immunogenicity of our baculovirus-derived WNV antigens was assessed in C57BL/6 mice.
The results showed that it took two to three vaccinations with 5 µg of our immunizing antigens to
induce a reliable immune response in the immunized mice and, in the case of gE, to induce a reliable
response of neutralizing antibodies against WNV (Supplementary Data 3, Figure S4).
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Figure 1. Schematic representation of the West Nile Virus (WNV) N-terminal polyprotein with
numbered amino acids (one-letter codes; beginning from the N-terminal (H2N) methionine (M))
and predicted transmembrane domains (bold numbers 1–7). The gE sequence is presented in blue
with its neutralization domain III in yellow. NS1 is depicted in grey. External parts of the sequence
(labeled extra) are depicted above the symbolic membrane and cytoplasmic parts are shown below
(labeled intra). For producing immunizing antigens, the external domains of gE and NS1, respectively,
were bracketed each with a synthetic N-terminal signal sequence and two C-terminal tag epitopes
(V5 and 6× his). For the ELISA antigens, the DIII domain of gE was supplemented with the synthetic
N-terminal signal sequence and with a C-terminal c-myc-GST-tail. Similarly, the NS1 fragment from
aa 792 to 1050 was bracketed with the same features. (Picture exported from PROTTER, Protter:
interactive protein feature visualization and integration with experimental proteomic data) [49].
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3.3. Immune Protection of Wild Type and TLR3KO Mice Following NS1- and/or gE-Vaccination
To assess the protective effects of NS1- and gE-vaccination against WNV in wild type or TLR3KO
animals, 10 groups of mice (Table 1) were immunized three times according to the scheme provided
in Figure S3. In the following section, the results are subdivided into serological responses against
WNV proteins prior to the challenge and various pathogenic outcomes following inoculating the mice
with WNV.
3.3.1. Serologic Responses Prior to Challenge
• Antibodies against NS1
On day 50 post-vaccination (pre-challenge), the sera from mock-immunized mice showed very
low reactions against the NS1-ELISA antigen, thus determining the background response to the NS1
ELISA antigen. The sera from WT mice immunized either with NS1 alone, an NS1 and gE combination,
or the commercial WNV vaccine showed a significantly elevated response, suggesting that all these
individuals had developed an antibody response against NS1 (Figure 2A). Interestingly, the seroreactions
of TLR3KO mice immunized with the NS1 antigen did not significantly differ from the reactions of
the mock-immunized mice. Thus, the immune response against NS1 of the TLR3KO mice remained
uncertain. However, TLR3KO mice immunized with the mixture of gE and NS1 or with the commercial
WNV vaccine (Figure 2B) showed seroreactions in the same range as WT mice, suggesting that they
had developed antibodies against NS1.
• Antibodies against gE
Additionally, at day 50, the sera from mock-immunized mice showed barely any reaction against
the gE-ELISA antigen, thus defining the very low level of negative reactions. Among the animals
immunized with gE alone, some individuals remained within this negative range. However, two out
of five individuals from the TLR3KO group (Figure 2D) and one out of five individuals from the WT
group (Figure 2C) showed clear seroreactions against the gE-ELISA antigen. Moreover, all individuals
immunized with the combination of gE and NS1 as well as those immunized with the commercial
vaccine showed very clear seroreactions against the gE-ELISA antigen. Thus, against expectations,
not all gE-only immunized animals had developed a measurable antibody response against gE by day
50. However, as soon as NS1 became part of the antigenic mixture, very clear antibody responses could
be measured.
3.3.2. Neutralizing Antibodies
A similar picture emerged upon performing the PRNT50 assay with the same sera: each two
out of five individuals immunized with gE alone (both WT and TLR3KO mice) showed neutralizing
activity against WNV. While NS1-immunized or mock-immunized individuals remained seronegative,
three out of three individuals from both the WT and TLR3KO groups showed high WNV-neutralizing
activity following application of the commercial vaccine. An interesting difference emerged among
the animals immunized with the combination of gE and NS1: three out of five WT animals developed
neutralizing antibodies (Figure 2E), whereas five out of five TLR3KO individuals that did the same
(Figure 2F). Thus, it seemed as if the development of neutralizing antibodies against WNV was
facilitated in the presence of the two antigens gE and NS1. Moreover, under these circumstances,
the TLR3KO mice developed a more consistent antibody response than WT animals.
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Figure 2. Antibody responses prior to WNV challenge infection. The groups of mice tested (see Table 
1) are indicated on the x-axis. Panels (A), (C), and (E) represent WT mice; panels (B), (D), and (F) 
represent TLR3KO mice. Each symbol represents an individual mouse; the horizontal line indicates 
the mean value for each group. Panels (A–D) show ELISA values as measured at OD450 nm (y-axis). 
Figure 2. Antibody responses prior to WNV challenge infection. The groups of mice tested (see Table 1)
are indicated on the x-axis. Panels (A), (C), and (E) represent WT mice; panels (B), (D), and (F) represent
TLR3KO mice. Each symbol represents an individual mouse; the horizontal line indicates the mean
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value for each group. Panels (A–D) show ELISA values as measured at OD450 nm (y-axis).
(A,B): ELISA for NS1 antibodies; (C,D): ELISA for gE antibodies. All sera were tested on the same plate.
Separated by a dotted line on the right of each panel (A–D) the value of a positive control is given,
which was determined by using an anti-C-myc monoclonal antibody for testing the amount of coated
antigen. Panels (E,F): WNV-neutralizing antibodies as detected by plaque reduction neutralization
assay (PRNT), with the titer indicated on the y-axis. The horizontal dotted line indicates the negative
cut-off value, which equals a serum dilution of 1:80, the lowest dilution used in the assay. The values
below this cut-off are fictional. Where applicable, one-way ANOVA with Tukey’s test for multiple
comparisons was used to investigate statistical differences between the groups. Significant differences
are indicated by asterisks.
3.4. Protection against WNV Infection and Disease in WT and TLR3KO Mice Following Immunization
The mice were infected with 105 pfu of WNV ITA09 post-immunization to assess the protective
efficacy of the different vaccinations and the pathogenic nature of the infection. The readouts are
subdivided below into survival, clinical scores, viral spread, and inflammation in the CNS.
3.4.1. Survival
At 3 weeks post challenge, all the members of the groups immunized with either gE or gE +
NS1 or commercial vaccine were still alive, including all those individuals who had not developed
a detectable amount of antibodies against gE. However, in the case of NS1 immunization without gE,
only two of five and three of five, respectively, of WT and TLR3KO mice survived (Figure 3A,B).
Within the mock-immunized control groups, three of five mice in the WT group showed severe WNV
infection, whereas all the mice in TLR3KO group succumbed to severe WNV infection and did not
survive. Thus, while there was no difference concerning case fatality between mock-immunized
and NS1-immunized WT mice, the number of TLR3KO mice succumbing to lethal WNV infection was
reduced in NS1-immunized mice compared to mock-immunized individuals.
Viruses 2019, 11, x FOR PEER REVIEW 10 of 24 
 
(A,B): ELISA for NS1 antibodies; (C,D): ELISA for gE antibodies. All sera were tested on the same 
plate. Separated by a dotted line on the right of each panel (A–D) the value of a positive control is 
given, which was determined by using an anti-C-myc monoclonal antibody for testing the amount of 
coated antigen. Panels (E,F): WNV-neutralizing antibodies as detected by plaque reduction 
neutralization assay (PRNT), with the titer indicated on the y-axis. The horizontal dotted line indicates 
the negative cut-off value, which equals a serum dilution of 1:80, the lowest dilution used in the assay. 
The values below this cut-off are fictional. Where applicable, one-way ANOVA with Tukey’s test for 
multiple comparisons was used to investigate statistical differences between the groups. Significant 
differences are indicated by asterisks. 
3.4. Protection Against WNV Infection and Disease in WT and TLR3KO Mice F llowing I munization 
The mice were infected with 105 pfu of WNV ITA09 post-i munization to assess the protective 
efficacy of the diff rent vaccinations and the pathogenic nature of the infection. The readouts are 
subdivided below into sur ival, clinical scores, viral spread, and infla mation in the CNS. 
3.4.1. Survival 
At 3 w eks post c all ,   e bers of the groups im unized with either gE or gE + NS1 
or commercial vaccine were still a ive, including all those individuals who had not eveloped a 
     . r, in the case of NS1 immunization without gE, 
only two of five and thr e of five, respectively, of WT and TLR3KO mice survived (Figure 3A,B). 
Within the mock-i munized control groups, three of five mice in the WT group showed severe WNV 
infection, whereas all the mice in TLR3KO group succumbed to severe WNV infection and did not 
survive. s,   as no difference concerning case fat lity between mock-immunized and 
NS1-immunized WT mice, the number of TLR3KO ice   lethal NV infection was 
reduced in NS1-i munized mice compared to mock-i munized ind viduals. 
 
Figure 3. Survival of mice after experimental WNV infection. (A) Mock immunized; (B) NS1 
immunized. Red dotted lines used to show WT mice; blue dotted lines used to indicate TLR3KO mice. 
The time in days is given on the x-axis, starting at the day of experimental inoculation with 100 LD50 
of WNV Italy 09. The y-axis gives the percentage of surviving animals (for additional information see 
Table 1). Note: In order to not overload the figure, the data of groups with a 100% survival rate were 
not included in this figure. 
3.4.2. Clinical Scores 
Mice were scored during the entire period of the experiment for clinical signs according to the 
criteria described in Table 2. Higher scores represent more severe clinical illness, whereas low scores 
are associated with mild courses. 
As shown in Figure 4, high clinical scores were observed in the mock-immunized groups as well 
as in the groups immunized with NS1/adjuvant alone, which relates well with the survival rate 
shown previously. Low clinical scores were observed among the groups immunized with 
Figure 3. Survival of mice after experimental WNV infection. (A) Mock immunized; (B) NS1 immunized.
Red dotted lines used to show WT mice; blue dotted lines used to indicate TLR3KO mice. The time
in days is given on the x-axis, starting at the day of experimental inoculation with 100 LD50 of WNV
Italy 09. The y-axis gives the percentage of surviving animals (for additional information see Table 1).
Note: In order to not overload the figure, the data of groups with a 100% survival rate were not included
in this figure.
3.4.2. Clinical Scores
Mice were scored during the entire period of the experiment for clinical signs according to
the criteria described in Table 2. Higher sco es represent more severe illness, whereas low
scores are a sociated with mild course .
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As shown in Figure 4, high clinical scores were observed in the mock-immunized groups as well
as in the groups immunized with NS1/adjuvant alone, which relates well with the survival rate shown
previously. Low clinical scores were observed among the groups immunized with gE/adjuvant alone.
Although most members of these groups had not developed detectable antibody responses against gE,
not one single individual developed severe signs of WNV-disease. Importantly, none of the animals
immunized with adjuvant and the combination of glycoprotein E and NS1 reached a clinical score.
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Figure 4. Clinical scores post challenge with WNV. Panels (A), (B), and (C) show data for wild
type mice; (D), (E), and (F) show data for TLR3KO mice. (A,D): mock-immunized animals;
(B,E): NS1-immunized animals; (C,F): gE-immunized animals. Each bar represents the cumulative
clinical score of one individual mouse at its day of euthanasia. The y-axis represents the individual mice
per immunized group having a total score of 1 or more. Mice counted as survivors were euthanized
at day 19 post challenge. The bars are color-coded as follows: black represents points allocated for
weight loss; red represents pain-associated behavior; purple represents physical changes. Note: In order
to not overload the figure with empty graphs, the data of mice immunized with both gE and NS1, all of
which did not show any measurable disease signs, are not included in this figure.
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Thus, animals immunized with the combination of gE and NS1 were clinically protected.
Animals immunized with gE alone, even those without detectable antibodies against gE, were
substantially protected from the disease, whereas NS1-immunized animals were hardly better protected
than mock-immunized animals. Regardless of the vaccine type, we observed no significant difference
between the clinical scores of WT and TLR3KO mice, respectively.
3.4.3. Viral Spread
Viremia is a clear sign of spread of the virus in the host. Therefore, plasma samples were
collected on days 2 and 4 post infection and analyzed for WNV RNA by quantitative real time
RT-PCR (RT-qPCR). The data of all animals with detectable viremia are presented in Figure 5A,B.
Viremia was indeed detected in all mock-immunized animals and in animals immunized with NS1
alone. As soon as gE was included in the vaccine, viremia was reduced, in some cases to undetectable
levels. Interestingly, this was indeed true for all gE-immunized animals, independently of their
gE antibody titers. Compared to day two, viremia was reduced on day 4 post infection. None of
the animals immunized with a gE-component was still viremic at this later time point.
It is understood that WNV reaches the internal organs following viremia [50]. Therefore, we also
analyzed the spleens and the brains of all WNV-inoculated animals for WNV RNA by RT-qPCR.
The results are summarized in Table 3.
Table 3. WNV RNA in brain and spleen following immunization and WNV challenge infection.
Immunization WT Mice TLR3KO
Brain a Spleen b Brain Spleen
gE 2/5 c 0/5 0/5 0/5
NS1 5/5 4/5 4/5 3/5
gE + NS1 1/5 0/5 0/5 0/5
Commercial vaccine 0/3 0/3 0/3 0/3
PBS + adjuvant 4/5 3/5 5/5 5/5
a,b Detection of WNV RNA in organ extracts by quantitative real time RT-PCR (RT-qPCR). c Number of positive
animals/number of tested animals.
Indeed, WNV-RNA was detected in the brains and spleens of most mock- or NS1-immunized
animals, independently of their genetic background. In WT mice, WNV-RNA was detected in
the spleens of all animals immunized with NS1 but only in three of five mock-immunized ones.
Interestingly, in the TLR3KO group, WNV-RNA in spleens was detected only in three of five mice
immunized with NS1 but in all mock-immunized mice (Figure 5C,D).
The brain seemed to be more sensitive for WNV than the spleen since WNV RNA was detected in
the brains of all 10 mock immunized animals (five WT and five TLR3KO) as well as in nine of the ten
NS1 immunized individuals (five of five WT and four of five TLR3KO). Moreover, WNV RNA in
brains was detected in two out of five WT mice immunized with gE alone and in one out of five WT
mice immunized with a combination of gE and NS1 (Figure 5E,F). Notably, these three animals had
previously been identified as early viremic (Figure 5A).
By contrast, WNV-RNA was neither detected in the brain or spleen of any of the animals vaccinated
with the commercial vaccine (three WT and three TLR3KO) nor in any of the TLR3KO mice immunized
either with gE alone or with a combination of gE and NS1.
Thus, in the absence of a vaccine containing gE, WNV invariably reached the brains of the inoculated
animals. Moreover, in three out of four animals with detectable viremia at day 2 post WNV inoculation,
the virus was later on also detected in the brain. Thus, early viremia was a good indicator for WNV
brain invasion.
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Figure 5. Levels of WNV RNA in the organs of WNV-infected mice. Separate panels are shown for
plasma (A and B are each split into day 2 on the left and day 4 on the right), spleen (C,D), and brain (E,F)
samples. Panels (A,C,E): WT mice; (B,D,F): TLR3KO mice. The loads of WNV in the individual samples
were determined by RT-qPCR and each dot in each panel represents one single animal. The y-axis of
each panel represents the logarithmic value of viral genome copies detected per mL of either blood
plasma or organ suspension. The individual groups of animals are listed on the x-axis. Note: Samples
which did not provide a Ct value, i.e. where WNV could not be detected, have been excluded from
the figure.
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3.4.4. CNS Inflammation
We subjected brain samples of each individual to histological examination. In addition,
we quantified the CNS-infiltrating neutrophils, lymphocytes, and monocytes in the infected animals
by flow cytometry. Finally, IFNγ and TNFα expression in the brain was determined by RT-qPCR
(Supplementary Data 4, Table S1).
Infiltrating cells: hematoxylin and eosin (H&E)-stained brain sections from all mice were screened
for perivascular infiltration of leukocytes as well as for necrotic and/or apoptotic areas indicative of
CNS inflammation. Exemplary pictures for each scoring level are shown in Figure S5.
The results are shown in Figure 6A–B, where the animals are also stratified into those
with detectable WNV RNA in their brains and those without. All mice with detectable WNV
RNA in their brains, except one TLR3KO individual (H4, which had been immunized against NS1),
received a histological score of one or higher, whereas many mice without detectable WNV had a score
of zero. However, there was a great amount of overlap in the scores of one and two, suggesting that
histology alone was not a good indicator to discriminate between the two strata.
To refine these crude assessments, flow cytometric analysis (FACS) was used to quantify
the infiltrating immune cells in the brain of the infected mice. Briefly, neutrophils
(CD11b+Ly6G+), monocytes (CD11b+Ly6Chigh), and lymphocytes (CD45+CD11b-) were determined
(Supplementary Data 4, Table S1). Representative FACS plots and the gating strategy for each population
are shown in a supplementary figure (Supplementary Data 4, Figure S6. The results of this analysis are
summarized in Figure 6C–H.
Animals with detectable WNV RNA in their brains had significantly higher numbers of each
single infiltrating cell category than animals without WNV in their brains. However, there was still
significant overlap, particularly in the case of the neutrophils and monocytes.
Upon ranking of the data according to neutrophil counts, the lowest values among all mice were
observed with C2, a WT mouse that had been immunized against NS1 and had a significant amount of
WNV RNA in its brain. On the opposite side, the highest neutrophil counts were observed with K2,
a TLR3KO mouse, which had also the highest burden of WNV in its brain.
Upon ranking according to monocytes, the bottom eight positions with the lowest counts were
occupied by animals without WNV in their brains, which had been immunized against gE, either alone
or in combination with NS1. Both WT and TLR3KO mice were among them. Interestingly, the five top
positions with the highest monocyte counts were all occupied by mock-immunized TLR3KO mice
(group K) with variable amounts of WNV in their brains. These two extremes were separated by
an intermixed group of animals with or without WNV in their brains. However, the number of animals
with WNV in their brains generally increased with increasing monocyte counts.
Upon ranking for lymphocyte counts, the 24 bottom positions with the lowest cell counts were
all occupied by animals without WNV in their brains, whereas the 18 top positions were occupied
by animals with detectable WNV in their brains. Notably, only one single animal (H2) without
detectable WNV in its brain ranked within the range of the WNV-positive animals. Again, the five
mock-immunized TLR3KO mice (group K) ranked in five of the six top positions.
Notably, in the absence of WNV, the inflammatory cell counts were similar in the brains of
TLR3KO mice or their WT counterparts. However, in the presence of comparable WNV loads in their
brains (Figure 7A), the total infiltrating inflammatory cell count was highest in the mock-immunized
TLR3KO group (Figure 7B). More specifically, the monocyte counts in the mock-immunized TLR3KO
mice exceeded the corresponding counts of the other three groups by far (NS1-immunized TLR3KO
mice as well as NS1- or mock-immunized WT mice) (Figure 7C). Together, these data suggested that
an intact TLR3-pathway functioned to dampen the inflammatory cell invasion upon WNV invasion of
the brain and that WNV NS1 contributed to neural inflammation with a mechanism different from
repression of TLR3 signaling.
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Figure 6. Leukocyte infiltration upon WNV infection of the brain. The brains of all experimental wild
type (A,C,E,G) and TLR3KO mice (B,D,F,H) were subjected to histological scoring (A,B) and flow
cytometric analysis (FACS) for the detection and quantification of inflammatory cells, including
neutrophils (C,D), monocytes (E,F), and lymphocytes (G,D). To recognize the role of WNV in the context
of CNS inflammation, the individuals were stratified into those with detectable WNV RNA in their
brains (WNV+) and those without (WNV−). WNV+ individuals have been further color coded to
represent different groups: gE green, NS1 yellow, gE + NS1 blue, and mock red, respectively. In addition
to the individual values, the mean is also presented. The Mann-Whitney test was used to
Viruses 2019, 11, 603 16 of 23
investigate statistical differences between the groups. Significant differences are indicated by asterisks
with *, p < 0.05; ***, p < 0.001; ****, p < 0.0001.
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mice, respectively. (B) The number of granulocytes, monocytes, and lymphocytes were added to
each other to give the total amount of infiltrating inflammatory cells in the brains (y-axis) of the same
mice. (C) log monocyte counts in the brains (y-axis) of WNV-positive NS1- (black) and mock- (red)
immunized mice, respectively.
Cytokines represent another and more refined type of inflammatory indicator. IFNγ and TNFα
were selected as representative cytokines to address this issue. Therefore, all brain samples were
examined for the expression of IFNγ and TNFα, respectively, using RT-qPCR. To make the results
comparable among individuals and groups, beta-actin mRNA was used as a reference as described
in Materials and Methods. The results are shown in Figure 8, where the animals were also stratified
into those with detectable WNV RNA in their brains and those without. Indeed, all animals with
detectable WNV RNA in their brains showed also a 10- to 100-fold higher expression of interferon
gamma and TNFα mRNA compared to any animal without detectable WNV RNA. These observations
confirmed that WNV brain invasion was consistently associated with CNS inflammation. In the case of
TNFα expression, high expression levels had an obvious tendency to correlate with high WNV loads
in the brain [51].
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Figure 8. Cytokine response upon WNV infection of the brain. RNA was extracted from brains of all
experimental mice and analyzed for cytokine RNAs by qRT-PCR. The Ct values were set in relation to
beta-actin mRNA as described in Materials and Methods. On the y-axis, the results of these calculations
are shown as log10 values. The data were stratified into a group representing animals with WNV
RNA in their brain tissue (WNV+) and those without (WNV−). Panel (A): IFNγ mRNA in WT mice.
Panel (B): the same in TLR3KO mice. Panel (C): TNFα mRNA in WT mice. Panel (D): the same in
TLR3KO mice. All individual values as well as the mean are indicated.
In order to understand if there is a correlation between the viral load in the brain and cytokine
and cellular infiltration, a graph plot was made between the viral load in the brain and TNFα expression
or lymphocyte count. The level of TNFα expression correlated relatively well with the WNV titer
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in the brain, with an R2 value of 0.74 (Figure 9A). By contrast, the inflammatory cell counts in
the WNV-positive brains seemed not to be strongly influenced by viral loads. As a representative
example, the correlation of lymphocytes with WNV titers is shown (Figure 9B), with this correlation
having an R2 of 0.04. Although the difference was not statistically significant, TNFα and IFNγ levels
were higher in WNV-infected TLR3KO mice than WNV-infected WT mice.
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Figure 9. Viral load in the CNS correlates largely with TNFα expression but not with lymphocyte
counts. The WNV load in the brains of both WT and TLR3KO mice were expressed as log10 values
and paired with (A) log10 values of either TNFα mRNA or (B) with log10 values of lymphocyte counts
in the CNS of each individual before being presented in an X,Y graph. The regression formula as well
as the R2 values are indicated in each graph.
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4. Discussion
After establishing the production of ELISA- and immunizing-WNV antigens in the baculovirus
system (S1 through S3), we performed protective studies against WNV brain invasion in WT as well
as TLR3KO mice and studied the influences of the two mouse genotypes as well as prior immunization
against gE and NS1 towards the severity of brain inflammation. The salient features of our research
are as follows:
Despite some suboptimal antibody responses, immunization with a gE antigen provided a good
measure of protection against WNV brain invasion, while an additional benefit due to simultaneously
vaccinating against NS1 could not readily be detected, which was in agreement with previous
studies [13,18,23,27,52]. Indeed, WNV-RNA was detected in the brain of most mock- or solely
NS1-immunized animals, independent of their genetic background. Thus, in contrast to others,
we were unable to confirm the importance of either prior immunization against NS1 [16,42] or the TLR3
receptor as a mediator for WNV entry to the brain [39]. Similarly, the viral loads in the brains of WT
and TLR3KO mice, respectively, did not significantly differ between the two genotypes, which was
true for both groups of mice (mock-vaccinated and NS1-vaccinated). A major limitation of our study
is the small number of animals used in experiments, which might have been insufficient to detect
subtle but significant differences, especially if considering the experimental variation and disease
duration, which may occur in mice inoculated with WNV [53]. Although further investigation in
larger experimental groups is required to support the results of our study, a comprehensive analysis of
factors contributing to encephalitis allowed us to identify a role for NS1 in enhancing the infiltration of
immune-inflammatory cells in the WNV-infected brain of TLR3-deficient mice.
Even if high WNV RNA loads were detected in the brains of both wild type and TLR3KO
mice (Figure 5E,F and Figure 7A), the mock-vaccinated TLR3KO mice showed the highest degree
of inflammatory cell invasion to the brain as a consequence of WNV neuroinvasion (Figure 7B).
This observation suggested that the intact TLR3 pathway in WT mice contributed to dampening
of the brain inflammation as a consequence of WNV invasion, conceivably through activation of
downstream effectors and the interferon response [54]. This observation is in agreement with a previous
report, showing that the absence of the TLR3 receptor led to increased inflammation in the brains of
WNV-infected mice as a consequence of increased viral loads [38,55].
The most interesting observations in our study were made with NS1-immunized mice. In fact,
NS1-immunized TLR3KO mice exhibited less inflammatory cell infiltration (mainly monocytes,
Figure 7C) upon WNV infection than mock-immunized TLR3KO mice, at viral loads comparable
with that detected in control WT mice. Further studies are needed to clarify the mechanisms of
protection of TLR3-deficient mice against WNV neuroinvasion and brain inflammation through
immunization with NS1. Based on the results of our study, we hypothesize that TLR3 deficiency led
to an impaired innate immune response and hence to unrestricted viral infection and replication in
neurons, brain inflammation with infiltration of inflammatory CD11b+Ly6Chigh monocytes, production
of proinflammatory cytokines, and increased permeability of the blood–brain barrier, as also described
in TLR3-deficient mice infected with Japanese encephalitis virus, a neurotropic flavivirus that is
very similar to WNV [56]. WNV NS1, besides inhibiting the TLR3 pathway, has a direct effect
on the permeability of the blood–brain barrier, and this effect could be synergistic in mice with
TLR3 deficiency. Immunization against NS1 could prevent damage to the blood–brain barrier,
with mechanisms that are independent from TLR3, but are relevant in the context of an impaired innate
immunity. In contrast to others, we have not observed adverse effects upon immunization with NS1 [37].
While further studies using various WNV strains in appropriate animal models, particularly non-human
primates, are warranted to clarify the interplay between WNV NS1 and the host TLR3-dependent
innate immune response, our findings highlight the beneficial effect of immunization with NS1 in
reducing neuroinflammation upon WNV infection in individuals with impaired innate immunity.
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5. Conclusions
In our experiments, the degree of inflammation measured in the brain was affected by viral load,
TLR3 signaling, and previous immunization again NS1. Viral load in the brain had a dose-dependent
effect on TNF alpha expression in both WT and TLR3KO mice, whereas the degree of cellular infiltration
in WNV-infected brains was less severe in mice with an intact TLR3 pathway than in those with TLR3
deficiency. At variance, TLR3KO mice immunized against WNV NS1 showed reduced inflammatory
cell infiltration, which was comparable to the degree observed in WT mice. Apart from the fact that gE
and NS1 seemed to adjuvant each other, inclusion of NS1 into WNV vaccines may be considered in
order to extend protection against neuroinvasive WNV to individuals with genetic or functional defects
of innate antiviral immunity. With respect to potential animal species-specific adverse effects attributed
by others to immunization with NS1 [37], it would be crucial to address this issue in non-human
primate models.
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